SlideShare a Scribd company logo
1Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Dr. Basavaraj K. Nanjwade
Principal Scientist
Trroy Life Sciences Pvt Ltd
C-14, New Town Yelhanka
Bangalore-560064, Karnataka, India
DEVELOPMENT OF CLINICAL
DRUG PRODUCT
CONTENT
• All dosage forms
• Clinical Pharmacology
• Clinical Pharmacokinetics
• Clinical Pharmacodynamics
• Clinical dose range,
• Clinical Trials
• Clinical Packaging (Primary)
• Clinical Packaging (Secondary)
• Clinical Storage & Distribution
• Quality by Design (QbD)
• Clinical Design Space
2Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
All dosage forms
• Immediate and modified release capsules
• Immediate and modified release tablets
• Fixed dose combination products
• Powder/granule filled sachets
• Multi-particulates (bead/pellets into capsules)
• Minitablets
• MUPS (Multiple Unit Pellet System)
3Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Pharmacology
• Clinical Pharmacology promotes the rational use of
medications in humans by studying their restorative
effect to amplify the drugs effect and reduce the side
effects.
• Clinical Pharmacology educates healthcare
professionals on a range of topics that involve the
interaction between drugs and humans.
4Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Pharmacology
5Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Pharmacokinetics
• Drug design, development and formulation strategies
used to optimise binding site interactions of modified
lead compounds were described earlier.
• A compound with optimised binding site interactions
may be susceptible to enzymatic degradation.
• Methods used to improve drug absorption, distribution,
site-specificity, and metabolic stability must be used
alongside strategies used to improve binding site
interactions.
Aditya Bangalore Institute of Pharmacy Education and Research 629/11/2018
Clinical Pharmacokinetics
Aditya Bangalore Institute of Pharmacy Education and Research 729/11/2018
Clinical Pharmacokinetics
8Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Drug Formulation for Oral Route
• Log P is less than +5
• Molecular mass is less than 500 Da
• Hydrogen bond acceptors must not be greater than
10
• Hydrogen bond donors must not be greater than 5
Aditya Bangalore Institute of Pharmacy Education and Research 929/11/2018
Formulation and Development
10Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Pharmacodynamics
• The drug with tissue receptors located either in cell
membranes or in the intracellular fluid.
• Some drugs acting at the same receptor (or tissue)
differ in the magnitude of the biological responses
that they can achieve (i.e. their 'efficacy') and the
amount of the drug required to achieve a response
(i.e. their 'potency').
11Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Pharmacodynamics
12Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical dose range
• A typical dose-ranging study may include four
groups: a placebo group, low-dose group, medium-
dose group and a high-dose group.
• The maximum tolerable dose (MTD) information is
necessary to be able to design such groups and
therefore dose-ranging studies are usually designed
after the availability of MTD information.
13Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical dose range
14Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Trials
• Clinical trials are research studies performed in
people that are aimed at evaluating a medical,
surgical, or behavioral intervention.
• They are the primary way that researchers find out if
a new treatment, like a new drug or diet or medical
device (for example, a pacemaker) is safe and
effective in people.
15Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Phases of Clinical Trials
• Clinical trials advance through four phases to test a
treatment, find the appropriate dosage, and look for
side effects.
• Clinical trials of drugs are usually described based on
their phase.
• The FDA typically requires Phase I, II, and III trials
to be conducted to determine if the drug can be
approved for use.
16Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Trials
17Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Phase I Clinical Trial
(INITIAL SAFETY TESTING IN A SMALL GROUP OF HEALTHY VOLUNTEERS )
• In Phase I trials the candidate drug is tested in people for the first
time.
• These studies are usually conducted with a small number of healthy
volunteers, generally 100 or less.
• The main goal of a Phase I trial is to assess the safety of the
medicine when used in humans.
• Researchers look at the pharmacokinetics of a drug: How is it
absorbed?
• How is it metabolized and eliminated from the body?
• They also study the drug’s pharmacodynamics: Does it cause side
effects?
• These closely monitored trials are designed to help researchers
determine what the safe dosing range is and if the candidate
medicine should move on to the next stage of development.
18Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Phase I
• Patients: 20 to 100 healthy volunteers or people with
the disease/condition.
• Length of Study: Several months
• Purpose: Safety and dosage
• Percentage of Drugs that Move to the next Phase
70%
19Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Study Types Included
• Safety & Tolerability studies (Single/ multiple dose in
patients or healthy volunteers)
• Oncology studies in patients with tolerability / MTD
as primary endpoint (efficacy might be a secondary
endpoint)
• Drug-Drug interaction & Food Effect
• PK in renal or hepatic impaired patients
Aditya Bangalore Institute of Pharmacy Education and Research 2029/11/2018
Phase II Clinical Trial
(ASSESS SAFETY AND EFFICACY IN A SMALL GROUP OF PATIENTS)
• In Phase II trials researchers evaluate the candidate
drug’s effectiveness in 100 to 500 patient volunteers
with the disease or condition under study.
• Researchers also analyze optimal dose strength and
schedules for using the drug and examine the possible
short-term side effects (adverse events) and risks
associated with the drug.
• If the drug continues to show promise, they prepare
for the much larger Phase III trials.
21Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Phase II
• Phase IIA: Exploratory (non-pivotal) study that has
clinical efficacy, Pharmacodynamics or biological
activity as primary endpoint, conducted in patients or
healthy volunteers.
• Phase IIB: Definite dose range finding study in
patients with efficacy as primary endpoint.
Aditya Bangalore Institute of Pharmacy Education and Research 2229/11/2018
Phase II
• Patients: Up to several hundred people with the
disease/condition.
• Length of Study: Several months to 2 years
• Purpose: Efficacy and side effects
• Percentage of Drugs that Move to the Next Phase
33%
23Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Study Type Included
• Proof of concept, efficacy, or mechanism
• Mechanistic studies
• Dose range exploration
• Pilot studies
• Definite dose finding studies
• Extension studies of Phase IIB studies
Aditya Bangalore Institute of Pharmacy Education and Research 2429/11/2018
Phase III Clinical Trial
(DEMONSTRATE SAFETY AND EFFICACY IN A LARGE GROUP OF PATIENTS)
• Phase III trials generate statistically significant data about
the safety, efficacy and the overall benefit-risk
relationship of the investigational medicine.
• Phase III trials may enroll 100 to 5,000 patients or more
across numerous clinical trials sites around the world.
• This phase of research is essential in determining whether
the drug is safe and effective.
• It also provides the basis for labeling instructions to help
ensure proper use of the drug (e.g., information on
potential interactions with other medicines, specific
dosing instructions, etc.)
25Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Phase III
• Patients: 100 to 5000 volunteers who have the
disease or condition
• Length of Study: 1 to 4 years
• Purpose: Efficacy and monitoring of adverse
reactions
• Percentage of Drugs that Move to the Next Phase
25-30%
26Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Phase III
• Phase IIIA: A Pivotal study that is a trial designed &
executed to get statistically significant evidence of
efficacy and safety as required NDA/ sNDA approval. It
also provides the basis for labeling instructions to help
ensure proper use of the drug (e.g., information on
potential interactions with other medicines, specific
dosing instructions, etc.)
• Phase IIIB: A study started prior to approval and whose
primary intention is support of publications rather than
registration or label changes. The results are not intended
to be included in the submission dossier.
Aditya Bangalore Institute of Pharmacy Education and Research 2729/11/2018
Study Time Included
• Pivotal studies (vs placebo/comparator)
• Long term safety studies for registration
• Local registration studies
• Post marketing study commitments
• Phase IIIA extension studies
• Studies intended to support publication, claims or
to prepare launch, which start before approval but
are not intended for Regulatory submissions
Aditya Bangalore Institute of Pharmacy Education and Research 2829/11/2018
Phase IV
• Phase IV: A study started after approval with primary
intention to support publications rather than
registration or label changes.
• The results are not intended to be included in a
submission dossier.
Aditya Bangalore Institute of Pharmacy Education and Research 2929/11/2018
Phase IV Clinical Trial
• Patients: Several thousand volunteers who have the
disease/condition
• Purpose: Safety and efficacy
30Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Packaging (Primary)
• Blistering
• Wallet Cards
• Bottling
• Enhanced Containment and Potent Products
31Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Blistering
32Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Wallet Cards
33Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Bottling
34Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Enhanced Containment and
Potent Products
35Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Packaging (Secondary)
• Secondary Labelling and Kitting of Clinical Supplies
• Flexible Clinical Supply Solutions
• Label Generation, Printing and Checking
• Biological Products
36Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Clinical Storage & Distribution
• Storage
• Distribution
• Global Depot Network
• Direct-to-patient
37Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
Steps in Pharmaceutical Products
Aditya Bangalore Institute of Pharmacy Education and Research 3829/11/2018
Quality by Design (QbD)
• QbD became the answer to assisting both the industry
and FDA to move toward a more scientific, risk-
based, holistic and proactive approach to
pharmaceutical development.
• In the QbD paradigm, a product is designed so that it
will meet its desired clinical performance.
Aditya Bangalore Institute of Pharmacy Education and Research 3929/11/2018
Medicines research
Aditya Bangalore Institute of Pharmacy Education and Research 4029/11/2018
Clinical Design Space
• The concept of clinical design space can be used to
quantify the clinical experience with a product.
• The size of the clinical design space for a given
product will depend on the number of manufactured
lots put in the clinic.
Aditya Bangalore Institute of Pharmacy Education and Research 4129/11/2018
Aditya Bangalore Institute of Pharmacy Education and Research 4229/11/2018
THANK YOUE-mail: nanjwadebk @gmail.com
Aditya Bangalore Institute of Pharmacy Education and Research 4329/11/2018

More Related Content

What's hot

Product development.
Product development.Product development.
Product development.
KH. Hussan Reza
 
Drug Development Process
Drug Development ProcessDrug Development Process
Drug Development ProcessClifford Mintz
 
Technology transfer
Technology transferTechnology transfer
Technology transfer
PRANJAY PATIL
 
NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)
Suvarta Maru
 
Usfda
UsfdaUsfda
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalence
muliksudip
 
USFDA
USFDAUSFDA
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
GOKULAKRISHNAN S
 
applications of pharmacokinetics in drug development
applications of pharmacokinetics in drug developmentapplications of pharmacokinetics in drug development
applications of pharmacokinetics in drug development
RitikaVaishnav1
 
product formulation and development
product formulation and developmentproduct formulation and development
product formulation and development
kalyaniArisettti
 
Stages of drug development
Stages of drug developmentStages of drug development
Stages of drug development
AakankshaPriya1
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical Industry
Rama Shukla
 
USFDA
USFDAUSFDA
Pilot plant scale up techniques
Pilot plant scale up techniquesPilot plant scale up techniques
Pilot plant scale up techniques
Dr Gajanan Sanap
 
Paragraph iii anda filing
Paragraph iii anda filingParagraph iii anda filing
Paragraph iii anda filing
Harishankar Sahu
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochure
Gaurav Sharma
 
Drug Regulatory Systems in India
Drug Regulatory Systems in IndiaDrug Regulatory Systems in India
Drug Regulatory Systems in India
Chandra Mohan
 
New Drug Application (NDA) Filing
New Drug Application (NDA) Filing New Drug Application (NDA) Filing
New Drug Application (NDA) Filing
SimranDhiman12
 

What's hot (20)

Product development.
Product development.Product development.
Product development.
 
Drug Development Process
Drug Development ProcessDrug Development Process
Drug Development Process
 
Technology transfer
Technology transferTechnology transfer
Technology transfer
 
NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)
 
Usfda
UsfdaUsfda
Usfda
 
Bioavailability and bioequivalence
Bioavailability and bioequivalenceBioavailability and bioequivalence
Bioavailability and bioequivalence
 
USFDA
USFDAUSFDA
USFDA
 
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...
 
applications of pharmacokinetics in drug development
applications of pharmacokinetics in drug developmentapplications of pharmacokinetics in drug development
applications of pharmacokinetics in drug development
 
product formulation and development
product formulation and developmentproduct formulation and development
product formulation and development
 
Stages of drug development
Stages of drug developmentStages of drug development
Stages of drug development
 
New Drug Development Process
New Drug Development ProcessNew Drug Development Process
New Drug Development Process
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical Industry
 
USFDA
USFDAUSFDA
USFDA
 
Pilot plant scale up techniques
Pilot plant scale up techniquesPilot plant scale up techniques
Pilot plant scale up techniques
 
Paragraph iii anda filing
Paragraph iii anda filingParagraph iii anda filing
Paragraph iii anda filing
 
Investigator's brochure
Investigator's brochureInvestigator's brochure
Investigator's brochure
 
Drug Regulatory Systems in India
Drug Regulatory Systems in IndiaDrug Regulatory Systems in India
Drug Regulatory Systems in India
 
New Drug Application (NDA) Filing
New Drug Application (NDA) Filing New Drug Application (NDA) Filing
New Drug Application (NDA) Filing
 
Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory Affairs
 

Similar to Development of Clinical Formulation

Clinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural productsClinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural products
Prof. Dr. Basavaraj Nanjwade
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
Sirisha Annavarapu
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
Prof. Dr. Basavaraj Nanjwade
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
Prof. Dr. Basavaraj Nanjwade
 
Drug development process and clinical trial for UGs
Drug development process and clinical trial for UGsDrug development process and clinical trial for UGs
Drug development process and clinical trial for UGs
SameerKhasbage
 
ich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptx
JyotshnaDevi4
 
Clinical Trial Primer
Clinical Trial PrimerClinical Trial Primer
Clinical Trial Primer
Michael Passanante
 
Clinical drug development
Clinical drug developmentClinical drug development
Clinical drug development
Prof. Dr. Basavaraj Nanjwade
 
Applications of bio-pharmaceutics in new drug delivery
Applications of bio-pharmaceutics in new drug  deliveryApplications of bio-pharmaceutics in new drug  delivery
Applications of bio-pharmaceutics in new drug delivery
Akshata shettar
 
nda and phases of cr
nda and phases of crnda and phases of cr
nda and phases of cr
Rohit K.
 
Phases 3,4 and 5 of clinical trials
Phases 3,4 and 5 of  clinical trialsPhases 3,4 and 5 of  clinical trials
Phases 3,4 and 5 of clinical trials
DrShrey Bhatia
 
Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology
ABUBAKRANSARI2
 
Clincial trials and types
Clincial trials and typesClincial trials and types
Clincial trials and types
Koppala RVS Chaitanya
 
Phases of Clinical Trials
Phases of Clinical Trials Phases of Clinical Trials
Phases of Clinical Trials
ClinosolIndia
 
Clinical research basic things
Clinical research basic thingsClinical research basic things
Clinical research basic things
SRIJIL SREEDHARAN
 
Presentation (1)-1.pptx
Presentation (1)-1.pptxPresentation (1)-1.pptx
Presentation (1)-1.pptx
Jaibhagwan47
 
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptxClinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Ram Arya
 
CLINICAL TRIALS.pptx
CLINICAL TRIALS.pptxCLINICAL TRIALS.pptx
CLINICAL TRIALS.pptx
TejaswiniAsawa
 
Scope of pharmacology
Scope of pharmacologyScope of pharmacology
Scope of pharmacology
jireankita
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
rasika walunj
 

Similar to Development of Clinical Formulation (20)

Clinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural productsClinical studies and trials on traditional medicine and natural products
Clinical studies and trials on traditional medicine and natural products
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
 
Clinical drug design
Clinical drug designClinical drug design
Clinical drug design
 
Drug development process and clinical trial for UGs
Drug development process and clinical trial for UGsDrug development process and clinical trial for UGs
Drug development process and clinical trial for UGs
 
ich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptx
 
Clinical Trial Primer
Clinical Trial PrimerClinical Trial Primer
Clinical Trial Primer
 
Clinical drug development
Clinical drug developmentClinical drug development
Clinical drug development
 
Applications of bio-pharmaceutics in new drug delivery
Applications of bio-pharmaceutics in new drug  deliveryApplications of bio-pharmaceutics in new drug  delivery
Applications of bio-pharmaceutics in new drug delivery
 
nda and phases of cr
nda and phases of crnda and phases of cr
nda and phases of cr
 
Phases 3,4 and 5 of clinical trials
Phases 3,4 and 5 of  clinical trialsPhases 3,4 and 5 of  clinical trials
Phases 3,4 and 5 of clinical trials
 
Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology
 
Clincial trials and types
Clincial trials and typesClincial trials and types
Clincial trials and types
 
Phases of Clinical Trials
Phases of Clinical Trials Phases of Clinical Trials
Phases of Clinical Trials
 
Clinical research basic things
Clinical research basic thingsClinical research basic things
Clinical research basic things
 
Presentation (1)-1.pptx
Presentation (1)-1.pptxPresentation (1)-1.pptx
Presentation (1)-1.pptx
 
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptxClinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
 
CLINICAL TRIALS.pptx
CLINICAL TRIALS.pptxCLINICAL TRIALS.pptx
CLINICAL TRIALS.pptx
 
Scope of pharmacology
Scope of pharmacologyScope of pharmacology
Scope of pharmacology
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 

More from Prof. Dr. Basavaraj Nanjwade

Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Prof. Dr. Basavaraj Nanjwade
 
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
Current and Future  Aspects of AI In Drug Discovery  Design and Development.pptxCurrent and Future  Aspects of AI In Drug Discovery  Design and Development.pptx
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
Prof. Dr. Basavaraj Nanjwade
 
COVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.pptCOVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.ppt
Prof. Dr. Basavaraj Nanjwade
 
Good laboratory practices for pharmaceuticals and biopharmaceuticals
Good laboratory practices for pharmaceuticals  and  biopharmaceuticalsGood laboratory practices for pharmaceuticals  and  biopharmaceuticals
Good laboratory practices for pharmaceuticals and biopharmaceuticals
Prof. Dr. Basavaraj Nanjwade
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
Prof. Dr. Basavaraj Nanjwade
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
Prof. Dr. Basavaraj Nanjwade
 
Novel drug delivery system
Novel drug delivery systemNovel drug delivery system
Novel drug delivery system
Prof. Dr. Basavaraj Nanjwade
 
Packaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for PharmaceuticalsPackaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for Pharmaceuticals
Prof. Dr. Basavaraj Nanjwade
 
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage FormsQbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
Prof. Dr. Basavaraj Nanjwade
 
Opportunities and Future for Pharma Buddies
Opportunities and Future for Pharma BuddiesOpportunities and Future for Pharma Buddies
Opportunities and Future for Pharma Buddies
Prof. Dr. Basavaraj Nanjwade
 
QbD for Pharma Products Development
QbD for Pharma Products DevelopmentQbD for Pharma Products Development
QbD for Pharma Products Development
Prof. Dr. Basavaraj Nanjwade
 
Development, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological productsDevelopment, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological products
Prof. Dr. Basavaraj Nanjwade
 
Solid dosage forms (tablets)
Solid dosage forms (tablets)Solid dosage forms (tablets)
Solid dosage forms (tablets)
Prof. Dr. Basavaraj Nanjwade
 
Solid dosage forms (capsules)
Solid dosage forms (capsules)Solid dosage forms (capsules)
Solid dosage forms (capsules)
Prof. Dr. Basavaraj Nanjwade
 
Preparations in pharmacy of hospital
Preparations in pharmacy of hospitalPreparations in pharmacy of hospital
Preparations in pharmacy of hospital
Prof. Dr. Basavaraj Nanjwade
 
Injectable solutions
Injectable solutionsInjectable solutions
Injectable solutions
Prof. Dr. Basavaraj Nanjwade
 
Pharmacokinetics of drugs administered by intravenous route
Pharmacokinetics of drugs administered by intravenous routePharmacokinetics of drugs administered by intravenous route
Pharmacokinetics of drugs administered by intravenous route
Prof. Dr. Basavaraj Nanjwade
 
Pharmacokinetics of drug absorption
Pharmacokinetics of drug absorptionPharmacokinetics of drug absorption
Pharmacokinetics of drug absorption
Prof. Dr. Basavaraj Nanjwade
 
Hepatic clearance and elimination
Hepatic clearance and eliminationHepatic clearance and elimination
Hepatic clearance and elimination
Prof. Dr. Basavaraj Nanjwade
 

More from Prof. Dr. Basavaraj Nanjwade (20)

Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...Injectable,  Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
Injectable, Ophthalmic, Controlled-Release Solid Orals Considering Regulator...
 
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
Current and Future  Aspects of AI In Drug Discovery  Design and Development.pptxCurrent and Future  Aspects of AI In Drug Discovery  Design and Development.pptx
Current and Future Aspects of AI In Drug Discovery Design and Development.pptx
 
COVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.pptCOVID-19 and Novel Drug Delivery System.ppt
COVID-19 and Novel Drug Delivery System.ppt
 
Good laboratory practices for pharmaceuticals and biopharmaceuticals
Good laboratory practices for pharmaceuticals  and  biopharmaceuticalsGood laboratory practices for pharmaceuticals  and  biopharmaceuticals
Good laboratory practices for pharmaceuticals and biopharmaceuticals
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
 
Opportunities and future for pharmacist
Opportunities and future for pharmacistOpportunities and future for pharmacist
Opportunities and future for pharmacist
 
Novel drug delivery system
Novel drug delivery systemNovel drug delivery system
Novel drug delivery system
 
Packaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for PharmaceuticalsPackaging and Stability Requirements for Pharmaceuticals
Packaging and Stability Requirements for Pharmaceuticals
 
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage FormsQbD for Product Development of Solid Semisolid and Liquid Dosage Forms
QbD for Product Development of Solid Semisolid and Liquid Dosage Forms
 
Opportunities and Future for Pharma Buddies
Opportunities and Future for Pharma BuddiesOpportunities and Future for Pharma Buddies
Opportunities and Future for Pharma Buddies
 
QbD for Pharma Products Development
QbD for Pharma Products DevelopmentQbD for Pharma Products Development
QbD for Pharma Products Development
 
Development, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological productsDevelopment, safety and stability of biotechnological and biological products
Development, safety and stability of biotechnological and biological products
 
Solid dosage forms (tablets)
Solid dosage forms (tablets)Solid dosage forms (tablets)
Solid dosage forms (tablets)
 
Solid dosage forms (capsules)
Solid dosage forms (capsules)Solid dosage forms (capsules)
Solid dosage forms (capsules)
 
Preparations in pharmacy of hospital
Preparations in pharmacy of hospitalPreparations in pharmacy of hospital
Preparations in pharmacy of hospital
 
Injectable solutions
Injectable solutionsInjectable solutions
Injectable solutions
 
Aerosols
AerosolsAerosols
Aerosols
 
Pharmacokinetics of drugs administered by intravenous route
Pharmacokinetics of drugs administered by intravenous routePharmacokinetics of drugs administered by intravenous route
Pharmacokinetics of drugs administered by intravenous route
 
Pharmacokinetics of drug absorption
Pharmacokinetics of drug absorptionPharmacokinetics of drug absorption
Pharmacokinetics of drug absorption
 
Hepatic clearance and elimination
Hepatic clearance and eliminationHepatic clearance and elimination
Hepatic clearance and elimination
 

Recently uploaded

Under Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's StrategyUnder Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's Strategy
Kenneth Kruk
 
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic IllnessesPrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx Program
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
Azreen Aj
 
PET CT beginners Guide covers some of the underrepresented topics in PET CT
PET CT  beginners Guide  covers some of the underrepresented topics  in PET CTPET CT  beginners Guide  covers some of the underrepresented topics  in PET CT
PET CT beginners Guide covers some of the underrepresented topics in PET CT
MiadAlsulami
 
Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...
Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...
Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...
salisonsalim1
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
nktiacc3
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
Dr Rachana Gujar
 
Rate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdfRate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdf
Rajarambapu College of Pharmacy Kasegaon Dist Sangli
 
Ginseng for Stamina Boost Your Energy and Endurance Naturally.pptx
Ginseng for Stamina Boost Your Energy and Endurance Naturally.pptxGinseng for Stamina Boost Your Energy and Endurance Naturally.pptx
Ginseng for Stamina Boost Your Energy and Endurance Naturally.pptx
SkyTagBioteq
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
AbdulMunim54
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Dinesh Chauhan
 
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptxThe Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
Global Travel Clinics
 
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
The Lifesciences Magazine
 
Cardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing studentCardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing student
fahmyahmed789
 
CANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' CaregiversCANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' Caregivers
CANSA The Cancer Association of South Africa
 
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
rowala30
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
Sachin Sharma
 
The positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experienceThe positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experience
SGRT Community
 
KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
NX Healthcare
 

Recently uploaded (20)

Under Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's StrategyUnder Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's Strategy
 
PrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic IllnessesPrudentRx's Function in the Management of Chronic Illnesses
PrudentRx's Function in the Management of Chronic Illnesses
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
 
PET CT beginners Guide covers some of the underrepresented topics in PET CT
PET CT  beginners Guide  covers some of the underrepresented topics  in PET CTPET CT  beginners Guide  covers some of the underrepresented topics  in PET CT
PET CT beginners Guide covers some of the underrepresented topics in PET CT
 
Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...
Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...
Mastoid cavity problem and obilteration presentation by Dr Salison Salim Pani...
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
 
Rate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdfRate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdf
 
Ginseng for Stamina Boost Your Energy and Endurance Naturally.pptx
Ginseng for Stamina Boost Your Energy and Endurance Naturally.pptxGinseng for Stamina Boost Your Energy and Endurance Naturally.pptx
Ginseng for Stamina Boost Your Energy and Endurance Naturally.pptx
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
 
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptxThe Importance of COVID-19 PCR Tests for Travel in 2024.pptx
The Importance of COVID-19 PCR Tests for Travel in 2024.pptx
 
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
 
Cardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing studentCardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing student
 
CANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' CaregiversCANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' Caregivers
 
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
 
The positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experienceThe positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experience
 
KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
 

Development of Clinical Formulation

  • 1. 1Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018 Dr. Basavaraj K. Nanjwade Principal Scientist Trroy Life Sciences Pvt Ltd C-14, New Town Yelhanka Bangalore-560064, Karnataka, India DEVELOPMENT OF CLINICAL DRUG PRODUCT
  • 2. CONTENT • All dosage forms • Clinical Pharmacology • Clinical Pharmacokinetics • Clinical Pharmacodynamics • Clinical dose range, • Clinical Trials • Clinical Packaging (Primary) • Clinical Packaging (Secondary) • Clinical Storage & Distribution • Quality by Design (QbD) • Clinical Design Space 2Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 3. All dosage forms • Immediate and modified release capsules • Immediate and modified release tablets • Fixed dose combination products • Powder/granule filled sachets • Multi-particulates (bead/pellets into capsules) • Minitablets • MUPS (Multiple Unit Pellet System) 3Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 4. Clinical Pharmacology • Clinical Pharmacology promotes the rational use of medications in humans by studying their restorative effect to amplify the drugs effect and reduce the side effects. • Clinical Pharmacology educates healthcare professionals on a range of topics that involve the interaction between drugs and humans. 4Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 5. Clinical Pharmacology 5Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 6. Pharmacokinetics • Drug design, development and formulation strategies used to optimise binding site interactions of modified lead compounds were described earlier. • A compound with optimised binding site interactions may be susceptible to enzymatic degradation. • Methods used to improve drug absorption, distribution, site-specificity, and metabolic stability must be used alongside strategies used to improve binding site interactions. Aditya Bangalore Institute of Pharmacy Education and Research 629/11/2018
  • 7. Clinical Pharmacokinetics Aditya Bangalore Institute of Pharmacy Education and Research 729/11/2018
  • 8. Clinical Pharmacokinetics 8Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 9. Drug Formulation for Oral Route • Log P is less than +5 • Molecular mass is less than 500 Da • Hydrogen bond acceptors must not be greater than 10 • Hydrogen bond donors must not be greater than 5 Aditya Bangalore Institute of Pharmacy Education and Research 929/11/2018
  • 10. Formulation and Development 10Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 11. Clinical Pharmacodynamics • The drug with tissue receptors located either in cell membranes or in the intracellular fluid. • Some drugs acting at the same receptor (or tissue) differ in the magnitude of the biological responses that they can achieve (i.e. their 'efficacy') and the amount of the drug required to achieve a response (i.e. their 'potency'). 11Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 12. Clinical Pharmacodynamics 12Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 13. Clinical dose range • A typical dose-ranging study may include four groups: a placebo group, low-dose group, medium- dose group and a high-dose group. • The maximum tolerable dose (MTD) information is necessary to be able to design such groups and therefore dose-ranging studies are usually designed after the availability of MTD information. 13Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 14. Clinical dose range 14Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 15. Clinical Trials • Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. • They are the primary way that researchers find out if a new treatment, like a new drug or diet or medical device (for example, a pacemaker) is safe and effective in people. 15Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 16. Phases of Clinical Trials • Clinical trials advance through four phases to test a treatment, find the appropriate dosage, and look for side effects. • Clinical trials of drugs are usually described based on their phase. • The FDA typically requires Phase I, II, and III trials to be conducted to determine if the drug can be approved for use. 16Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 17. Clinical Trials 17Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 18. Phase I Clinical Trial (INITIAL SAFETY TESTING IN A SMALL GROUP OF HEALTHY VOLUNTEERS ) • In Phase I trials the candidate drug is tested in people for the first time. • These studies are usually conducted with a small number of healthy volunteers, generally 100 or less. • The main goal of a Phase I trial is to assess the safety of the medicine when used in humans. • Researchers look at the pharmacokinetics of a drug: How is it absorbed? • How is it metabolized and eliminated from the body? • They also study the drug’s pharmacodynamics: Does it cause side effects? • These closely monitored trials are designed to help researchers determine what the safe dosing range is and if the candidate medicine should move on to the next stage of development. 18Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 19. Phase I • Patients: 20 to 100 healthy volunteers or people with the disease/condition. • Length of Study: Several months • Purpose: Safety and dosage • Percentage of Drugs that Move to the next Phase 70% 19Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 20. Study Types Included • Safety & Tolerability studies (Single/ multiple dose in patients or healthy volunteers) • Oncology studies in patients with tolerability / MTD as primary endpoint (efficacy might be a secondary endpoint) • Drug-Drug interaction & Food Effect • PK in renal or hepatic impaired patients Aditya Bangalore Institute of Pharmacy Education and Research 2029/11/2018
  • 21. Phase II Clinical Trial (ASSESS SAFETY AND EFFICACY IN A SMALL GROUP OF PATIENTS) • In Phase II trials researchers evaluate the candidate drug’s effectiveness in 100 to 500 patient volunteers with the disease or condition under study. • Researchers also analyze optimal dose strength and schedules for using the drug and examine the possible short-term side effects (adverse events) and risks associated with the drug. • If the drug continues to show promise, they prepare for the much larger Phase III trials. 21Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 22. Phase II • Phase IIA: Exploratory (non-pivotal) study that has clinical efficacy, Pharmacodynamics or biological activity as primary endpoint, conducted in patients or healthy volunteers. • Phase IIB: Definite dose range finding study in patients with efficacy as primary endpoint. Aditya Bangalore Institute of Pharmacy Education and Research 2229/11/2018
  • 23. Phase II • Patients: Up to several hundred people with the disease/condition. • Length of Study: Several months to 2 years • Purpose: Efficacy and side effects • Percentage of Drugs that Move to the Next Phase 33% 23Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 24. Study Type Included • Proof of concept, efficacy, or mechanism • Mechanistic studies • Dose range exploration • Pilot studies • Definite dose finding studies • Extension studies of Phase IIB studies Aditya Bangalore Institute of Pharmacy Education and Research 2429/11/2018
  • 25. Phase III Clinical Trial (DEMONSTRATE SAFETY AND EFFICACY IN A LARGE GROUP OF PATIENTS) • Phase III trials generate statistically significant data about the safety, efficacy and the overall benefit-risk relationship of the investigational medicine. • Phase III trials may enroll 100 to 5,000 patients or more across numerous clinical trials sites around the world. • This phase of research is essential in determining whether the drug is safe and effective. • It also provides the basis for labeling instructions to help ensure proper use of the drug (e.g., information on potential interactions with other medicines, specific dosing instructions, etc.) 25Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 26. Phase III • Patients: 100 to 5000 volunteers who have the disease or condition • Length of Study: 1 to 4 years • Purpose: Efficacy and monitoring of adverse reactions • Percentage of Drugs that Move to the Next Phase 25-30% 26Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 27. Phase III • Phase IIIA: A Pivotal study that is a trial designed & executed to get statistically significant evidence of efficacy and safety as required NDA/ sNDA approval. It also provides the basis for labeling instructions to help ensure proper use of the drug (e.g., information on potential interactions with other medicines, specific dosing instructions, etc.) • Phase IIIB: A study started prior to approval and whose primary intention is support of publications rather than registration or label changes. The results are not intended to be included in the submission dossier. Aditya Bangalore Institute of Pharmacy Education and Research 2729/11/2018
  • 28. Study Time Included • Pivotal studies (vs placebo/comparator) • Long term safety studies for registration • Local registration studies • Post marketing study commitments • Phase IIIA extension studies • Studies intended to support publication, claims or to prepare launch, which start before approval but are not intended for Regulatory submissions Aditya Bangalore Institute of Pharmacy Education and Research 2829/11/2018
  • 29. Phase IV • Phase IV: A study started after approval with primary intention to support publications rather than registration or label changes. • The results are not intended to be included in a submission dossier. Aditya Bangalore Institute of Pharmacy Education and Research 2929/11/2018
  • 30. Phase IV Clinical Trial • Patients: Several thousand volunteers who have the disease/condition • Purpose: Safety and efficacy 30Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 31. Clinical Packaging (Primary) • Blistering • Wallet Cards • Bottling • Enhanced Containment and Potent Products 31Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 32. Blistering 32Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 33. Wallet Cards 33Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 34. Bottling 34Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 35. Enhanced Containment and Potent Products 35Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 36. Clinical Packaging (Secondary) • Secondary Labelling and Kitting of Clinical Supplies • Flexible Clinical Supply Solutions • Label Generation, Printing and Checking • Biological Products 36Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 37. Clinical Storage & Distribution • Storage • Distribution • Global Depot Network • Direct-to-patient 37Aditya Bangalore Institute of Pharmacy Education and Research29/11/2018
  • 38. Steps in Pharmaceutical Products Aditya Bangalore Institute of Pharmacy Education and Research 3829/11/2018
  • 39. Quality by Design (QbD) • QbD became the answer to assisting both the industry and FDA to move toward a more scientific, risk- based, holistic and proactive approach to pharmaceutical development. • In the QbD paradigm, a product is designed so that it will meet its desired clinical performance. Aditya Bangalore Institute of Pharmacy Education and Research 3929/11/2018
  • 40. Medicines research Aditya Bangalore Institute of Pharmacy Education and Research 4029/11/2018
  • 41. Clinical Design Space • The concept of clinical design space can be used to quantify the clinical experience with a product. • The size of the clinical design space for a given product will depend on the number of manufactured lots put in the clinic. Aditya Bangalore Institute of Pharmacy Education and Research 4129/11/2018
  • 42. Aditya Bangalore Institute of Pharmacy Education and Research 4229/11/2018
  • 43. THANK YOUE-mail: nanjwadebk @gmail.com Aditya Bangalore Institute of Pharmacy Education and Research 4329/11/2018